[Proliferation and apoptosis effect of rosiglitazone on human ovarian cancer cell line SKOV3].

Article Details

Citation

Copy to clipboard

Ren QC, Peng ZL, Tan X

[Proliferation and apoptosis effect of rosiglitazone on human ovarian cancer cell line SKOV3].

Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 Mar;40(2):217-22.

PubMed ID

19462893 [ View in PubMed

]

Abstract

OBJECTIVE: To study the effect of PPARgamma, activated by Rosiglitazone (RSG), on the regulation of cell cycle and apoptosis in human ovarian cancer cell line SKOV3. METHODS: SKOV3 was treated with various levels of RSG (0.1, 1.0, 10 and 100 micromol/L), its proliferation was evaluated by MTT assay, apoptosis was determined by Hoechst33258 fluorescence and PI staining flow cytometry, and cell cycle analyzed by flow cytometry, respectively. The expression of PPARgamma, c-myc mRNA and protein were investigated by means of RT-PCR and immunocytochemistry respectively. RESULTS: MTT assay indicated that RSG could inhibit the proliferation of SKOV3 in a concentration-dependent and time-dependent pattern. PI staining flow cytometry data demonstrated that the apoptosis of SKOV3 and cell cycle was arrested at G1 stage induced by RSG in a concentration-dependent manner, after 24h inducing with RSG at the concentration of 10, 100 micromol/L, the apoptosis rates were 45.75% and 51.97% respectively, which were significantly higher than that of control group. Hoechst33258 fluorescence staining demonstrated that the apoptosis bodies were found in the SKOV3 treated with RSG. RT-PCR and immunocytochemistry indicated human ovarian cancer SKOV3 cells expressed PPARgamma. PPARgamma mRNA and protein expression increased, while c-myc mRNA and protein expression decreased in SKOV3 cells treated with RSG after 24 h. (P < 0.05). CONCLUSIONS: RSG significantly inhibits SKOV3 survival and induces its apoptosis by stoppage in G1 phase. The effect of growth inhibition is associated with downregulating expression of c-myc mRNA and protein via activation of PPARgamma.